Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, Wang X, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Shen K, Yu S, Li H, Tang L, Qiu R; study group of BG01-1323L.
Xu B, et al.
Ann Oncol. 2021 Feb;32(2):218-228. doi: 10.1016/j.annonc.2020.10.600. Epub 2020 Nov 11.
Ann Oncol. 2021.
PMID: 33188874
Free article.
Clinical Trial.
PATIENTS AND METHODS: In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m(2) IV daily, days 1-5, over 90 min) plus capecitabine (1000 mg/m(2) orally b.i.d., days 1-14) or capecitabine alone (1250 mg/m(2) orally b.i.d., days 1-14) every 21 days. …
PATIENTS AND METHODS: In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m(2) IV daily, days 1-5, over 90 min) plus cape …